Therapeutic Effects of Apremilast on Enthesitis and Dactylitis in Real Clinical Setting : An Italian Multicenter Study
INTRODUCTION: Enthesitis and dactylitis are difficult-to-treat features of psoriatic arthritis (PsA), leading to disability and affecting quality of life.
OBJECTIVE: The aim of this study is to evaluate enthesitis (using the Leed enthesitis index (LEI)) and dactylitis at 6 and 12 months in patients treated with apremilast.
METHODS: Patients affected by PsA from fifteen Italian rheumatological referral centers were screened. The inclusion criteria were: (a) enthesitis or dactylitisphenotype; (b) treatment with apremilast 30 mg bid. Clinical and treatment history, including PsA disease activity, were recorded. Mann-Whitney and chi-squared tests were used to assess the differences between independent groups, and Wilcoxon matched pairs signed-rank test assessed the differences between dependent samples. A p-value of <0.05 was considered statistically significant.
RESULTS: The Eph cohort consisted of 118 patients (median LEI 3); the Dph cohort included 96 patients with a median dactylitis of 1 (IQR 1-2). According to an intention to treat analysis, 25% and 34% of patients with enthesitis achieved remission (i.e., LEI = 0) in T1 and T2. The remission of dactylitis was 47% in T1 and 44% in T2. The per protocol analysis (patients observed for at least 12 months) showed that both dactylitis and LEI significantly improved in T1 (median LEI 1 (IQR 1-3)) and T2 (median LEI 0 (IQR 1-2)).
CONCLUSION: Eph and Dph PsA patients treated with apremilast experienced a significant improvement in enthesitis and dactylitis activity. After 1 year, enthesitis and dactylitis remission was achieved in more than one-third of patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 12(2023), 12 vom: 07. Juni |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Apremilast |
|---|
| Anmerkungen: |
Date Revised 01.07.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm12123892 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35874900X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35874900X | ||
| 003 | DE-627 | ||
| 005 | 20231226075412.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm12123892 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1195.xml |
| 035 | |a (DE-627)NLM35874900X | ||
| 035 | |a (NLM)37373587 | ||
| 035 | |a (PII)3892 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lo Gullo, Alberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic Effects of Apremilast on Enthesitis and Dactylitis in Real Clinical Setting |b An Italian Multicenter Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.07.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a INTRODUCTION: Enthesitis and dactylitis are difficult-to-treat features of psoriatic arthritis (PsA), leading to disability and affecting quality of life | ||
| 520 | |a OBJECTIVE: The aim of this study is to evaluate enthesitis (using the Leed enthesitis index (LEI)) and dactylitis at 6 and 12 months in patients treated with apremilast | ||
| 520 | |a METHODS: Patients affected by PsA from fifteen Italian rheumatological referral centers were screened. The inclusion criteria were: (a) enthesitis or dactylitisphenotype; (b) treatment with apremilast 30 mg bid. Clinical and treatment history, including PsA disease activity, were recorded. Mann-Whitney and chi-squared tests were used to assess the differences between independent groups, and Wilcoxon matched pairs signed-rank test assessed the differences between dependent samples. A p-value of <0.05 was considered statistically significant | ||
| 520 | |a RESULTS: The Eph cohort consisted of 118 patients (median LEI 3); the Dph cohort included 96 patients with a median dactylitis of 1 (IQR 1-2). According to an intention to treat analysis, 25% and 34% of patients with enthesitis achieved remission (i.e., LEI = 0) in T1 and T2. The remission of dactylitis was 47% in T1 and 44% in T2. The per protocol analysis (patients observed for at least 12 months) showed that both dactylitis and LEI significantly improved in T1 (median LEI 1 (IQR 1-3)) and T2 (median LEI 0 (IQR 1-2)) | ||
| 520 | |a CONCLUSION: Eph and Dph PsA patients treated with apremilast experienced a significant improvement in enthesitis and dactylitis activity. After 1 year, enthesitis and dactylitis remission was achieved in more than one-third of patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a apremilast | |
| 650 | 4 | |a dactylitis | |
| 650 | 4 | |a enthesitis | |
| 650 | 4 | |a psoriatic arthritis | |
| 700 | 1 | |a Becciolini, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Parisi, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Del Medico, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Farina, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Visalli, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Dal Bosco, Ylenia |e verfasserin |4 aut | |
| 700 | 1 | |a Molica Colella, Aldo Biagio |e verfasserin |4 aut | |
| 700 | 1 | |a Lumetti, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Caccavale, Rosalba |e verfasserin |4 aut | |
| 700 | 1 | |a Scolieri, Palma |e verfasserin |4 aut | |
| 700 | 1 | |a Andracco, Romina |e verfasserin |4 aut | |
| 700 | 1 | |a Girelli, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Bravi, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Colina, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Volpe, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Ianniello, Aurora |e verfasserin |4 aut | |
| 700 | 1 | |a Ditto, Maria Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Nucera, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Franchina, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Platé, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Di Donato, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Amato, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Salvarani, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Bernardi, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Lucchini, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a De Lucia, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Molica Colella, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Santilli, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Mansueto, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrero, Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Marchetta, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Arrigoni, Eugenio |e verfasserin |4 aut | |
| 700 | 1 | |a Foti, Rosario |e verfasserin |4 aut | |
| 700 | 1 | |a Sandri, Gilda |e verfasserin |4 aut | |
| 700 | 1 | |a Bruzzese, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Paroli, Marino |e verfasserin |4 aut | |
| 700 | 1 | |a Fusaro, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Ariani, Alarico |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 12(2023), 12 vom: 07. Juni |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:12 |g day:07 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm12123892 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 12 |b 07 |c 06 | ||